Proteomics niche Target potential partnerships in drug discovery and biomarker development by leveraging Proteome Sciences' proprietary workflows (SysQuant, TMTMS2, Super-Depletion, TMTcalibrator) and their expertise across tissues, plasma, CSF, and solid tissues to support pharma and diagnostics clients.

Mass spectrometry capability Explore sales opportunities around investment in advanced instrumentation and capacity expansion, such as Exploris mass spectrometers, to meet rising demand for chemoproteomics services and high-sensitivity biomarker assays.

Biomarker leadership Position offerings around discovery and validation of novel protein biomarkers for neurodegenerative diseases, cancer, and stroke, with services spanning discovery, prognosis, and treatment monitoring to attract biotech and pharma customers requiring robust biomarker pipelines.

Global collaboration Leverage the Frankfurt ISO 9001:2015 and GCLP certified facility to reassure potential clients about quality and regulatory-compliant proteomics workflows, encouraging partnerships with large pharma and CROs seeking compliant outsourcing partners.

Recent momentum Target opportunities arising from their ongoing growth and client interest at major mass spectrometry conferences, and proximity to financing for capacity expansion; use this narrative to create urgency with potential customers needing scalable proteomics services.